Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.215 USD | +1.42% | -2.31% | -2.43% |
Financials (USD)
Sales 2024 * | 50.06M | Sales 2025 * | 51.85M | Capitalization | 441M |
---|---|---|---|---|---|
Net income 2024 * | -84M | Net income 2025 * | -107M | EV / Sales 2024 * | 1.74 x |
Net cash position 2024 * | 353M | Net cash position 2025 * | 365M | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-5.38
x | P/E ratio 2025 * |
-4.83
x | Employees | 162 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.09% |
Latest transcript on Voyager Therapeutics, Inc.
1 day | -2.41% | ||
1 week | -6.14% | ||
Current month | +3.58% | ||
1 month | +5.88% | ||
3 months | -0.98% | ||
6 months | +17.73% | ||
Current year | -4.03% |
Managers | Title | Age | Since |
---|---|---|---|
Alfred Sandrock
CEO | Chief Executive Officer | 67 | 22-02-28 |
Robin Swartz
DFI | Director of Finance/CFO | 53 | 21-08-31 |
Michael Higgins
CHM | Chairman | 61 | 15-07-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Scangos
BRD | Director/Board Member | 76 | 23-05-08 |
James Geraghty
BRD | Director/Board Member | 69 | 13-12-31 |
Glenn F. Pierce
BRD | Director/Board Member | 68 | 17-01-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 8.235 | +1.67% | 81 835 |
24-05-23 | 8.1 | -2.41% | 503,030 |
24-05-22 | 8.3 | -1.66% | 358,125 |
24-05-21 | 8.44 | -0.12% | 314,405 |
24-05-20 | 8.45 | +0.24% | 562,180 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.03% | 441M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+46.11% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- VYGR Stock